β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.

[1]  A. Harris,et al.  Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer , 2015, Oncotarget.

[2]  T. Dittmar,et al.  Cytosolic calcium measurements in renal epithelial cells by flow cytometry. , 2014, Journal of visualized experiments : JoVE.

[3]  T. Dittmar,et al.  Analysis of cell migration within a three-dimensional collagen matrix. , 2014, Journal of visualized experiments : JoVE.

[4]  D. Klimstra,et al.  EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer , 2014, International journal of cancer.

[5]  J. Wulfkuhle,et al.  An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models , 2013, Breast Cancer Research.

[6]  M. Masu,et al.  ErbB2 Dephosphorylation and Anti-Proliferative Effects of Neuregulin-1 in ErbB2-Overexpressing Cells; Re-evaluation of Their Low-Affinity Interaction , 2013, Scientific Reports.

[7]  K. Pantel,et al.  The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC‐γ1 signalling in breast cancer cell migration and dissemination , 2012, The Journal of pathology.

[8]  K. Haglund,et al.  The role of ubiquitylation in receptor endocytosis and endosomal sorting , 2012, Journal of Cell Science.

[9]  J. Segall,et al.  Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis , 2011, Oncogene.

[10]  Haluk Resat,et al.  Bmc Cell Biology Her/erbb Receptor Interactions and Signaling Patterns in Human Mammary Epithelial Cells , 2009 .

[11]  M. Kazanietz,et al.  Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1. , 2008, The Biochemical journal.

[12]  T. Dittmar,et al.  The neurotransmitter GABA is a potent inhibitor of the stromal cell-derived factor-1alpha induced migration of adult CD133+ hematopoietic stem and progenitor cells. , 2007, Stem cells and development.

[13]  Ian O Ellis,et al.  Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells , 2007, Breast Cancer Research.

[14]  M. Moasser,et al.  Targeting HER proteins in cancer therapy and the role of the non-target HER3 , 2007, British Journal of Cancer.

[15]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[16]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[17]  J. Segall,et al.  ErbB3-dependent motility and intravasation in breast cancer metastasis. , 2006, Cancer research.

[18]  J. Menéndez,et al.  αVβ3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer , 2005, Oncogene.

[19]  A. Thor,et al.  Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Thomas Dittmar,et al.  Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c‐erbB‐2 receptor via epidermal growth factor receptor , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Stefano Iacobelli,et al.  The mechanism involved in the regulation of phospholipase Cγ1 activity in cell migration , 2002, Oncogene.

[23]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[24]  L. E. Johannessen,et al.  Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies , 2002, The Journal of cell biology.

[25]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.

[26]  S. Eccles.  The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[27]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Assmann,et al.  c‐erbB‐2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  G. Carpenter,et al.  The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF Receptor* , 1999, The Journal of Biological Chemistry.

[30]  A. Wells,et al.  A Role for Phospholipase C-γ-mediated Signaling in Tumor Cell Invasion , 1999 .

[31]  Alan Wells,et al.  Effect of Epidermal Growth Factor Receptor Internalization on Regulation of the Phospholipase C-γ1 Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[32]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[33]  B. Geiger,et al.  Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.

[34]  D. Polk,et al.  Epidermal growth factor receptor-stimulated intestinal epithelial cell migration requires phospholipase C activity. , 1998, Gastroenterology.

[35]  J. Schlessinger,et al.  Activation of phospholipase Cγ by PI 3‐kinase‐induced PH domain‐mediated membrane targeting , 1998 .

[36]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[37]  S. Rhee,et al.  Regulation of Phosphoinositide-specific Phospholipase C Isozymes* , 1997, The Journal of Biological Chemistry.

[38]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[39]  L. Cook,et al.  A simplified method for Ca2+ flux measurement on isolated human B cells that uses flow cytometry , 1997, Clinical and diagnostic laboratory immunology.

[40]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[41]  F. Waldman,et al.  ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.

[42]  D A Lauffenburger,et al.  Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.

[43]  G. Carpenter,et al.  Individual epidermal growth factor receptor autophosphorylation sites do not stringently define association motifs for several SH2-containing proteins. , 1994, The Journal of biological chemistry.

[44]  A. Ullrich,et al.  Presence of SH2 domains of phospholipase C gamma 1 enhances substrate phosphorylation by increasing the affinity toward the epidermal growth factor receptor. , 1992, The Journal of biological chemistry.

[45]  A. Ullrich,et al.  SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high‐affinity binding site for SH2 domains of phospholipase C gamma. , 1992, The EMBO journal.

[46]  T. Pawson,et al.  The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC‐gamma. , 1990, The EMBO journal.

[47]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[48]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[49]  A. Wells,et al.  A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.